Phase II study of FOLFIRI plus Bevacitumab in the treatment of Japanese patients with advanced colorectal cancer.

ABSTRACT: Interventions: (1) Bevaciumab 5mg/Kg i.v. 90min. (2) CPT-11 150mg/m2 i.v. 90min. and Isovorin 200mg/m2 i.v. 90min. (3) 5-FU 400mg/m2 i.v. bolus and 5-FU 2400mg/m2 civ. 46 hours Primary outcome(s): Progression free survival Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2616929 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR